{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:55:01Z","timestamp":1770483301485,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.leukres.2011.07.014","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T21:48:20Z","timestamp":1312840100000},"page":"e223-e224","source":"Crossref","is-referenced-by-count":17,"title":["Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Stephanie J.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.07.014_bib0055","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 405.","DOI":"10.1182\/blood.V114.22.405.405"},{"key":"10.1016\/j.leukres.2011.07.014_bib0060","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Kaiser U, Balser C, et al. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas - Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 856.","DOI":"10.1182\/blood.V116.21.856.856"},{"key":"10.1016\/j.leukres.2011.07.014_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for pneumocystis carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.07.014_bib0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.07.014_bib0025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","article-title":"Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"Ohmachi","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2011.07.014_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.07.014_bib0035","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.07.014_bib0040","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.07.014_bib0045","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00432-003-0441-y","article-title":"Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer","volume":"129","author":"Klippstein","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.leukres.2011.07.014_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","article-title":"Optimal use of bendamustine in chronic lymphocytic leukemia non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611003432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611003432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T19:50:54Z","timestamp":1712692254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611003432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0145212611003432"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.07.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}